Latest Diabetes News

Recce Pharmaceuticals has won a significant Australian Government R&D tax incentive, unlocking up to A$85 million for its synthetic anti-infective programs worldwide, including a pivotal Phase 3 clinical trial.

Proteomics International's PromarkerD blood test shows clinically meaningful accuracy in predicting diabetic kidney disease among Aboriginal Australians, matching performance in non-Indigenous populations. This advancement offers a promising tool for early intervention in a high-risk group.

Proteomics International Laboratories has clarified that no undisclosed information explains its recent share price jump, pointing instead to recent Medicare reimbursement decisions and key product developments.

Recce Pharmaceuticals has secured a key patent in Hong Kong for its synthetic anti-infectives, reinforcing its intellectual property footprint in Asia and supporting its clinical and commercial ambitions in the region.

Proteomics International secures a key Medicare reimbursement rate for its PromarkerD test, a predictive diagnostic for diabetic kidney disease, marking a critical step in its US commercial rollout.

Proteomics International Laboratories has secured a $2.2 million Australian Government R&D tax rebate, reinforcing its financial position as it advances a promising pipeline of diagnostic tests based on its proprietary Promarker® technology.

Recce Pharmaceuticals has commenced patient dosing in its pivotal Phase 3 trial for diabetic foot infections in Indonesia, supported by promising antibacterial efficacy data and extended funding arrangements.

Zelira Therapeutics has made significant progress in its HOPE 1 clinical trial program, completing a key FDA submission and securing a $650,000 non-dilutive R&D loan facility to support ongoing development and working capital needs.

Proteomics International Laboratories has secured ISO 15189 certification and launched PromarkerD and PromarkerEso nationally in Australia, while advancing US reimbursement pathways and preparing for leadership transition.

ReNerve Limited has achieved its first commercial sales of the EmpliQ™ amniotic tissue products, marking a significant step in its transition from R&D to commercialisation. The EmpliQ™ range complements its existing nerve repair solutions and targets a growing global wound care market.

Recce Pharmaceuticals has initiated patient dosing in its pivotal Phase 3 trial for diabetic foot infections in Indonesia, targeting a significant market with high diabetes prevalence. Interim results expected in early 2026 could accelerate regulatory approval and commercial launch.

ReNerve Ltd has launched its Empliq product range, marking its entry into the dermal and amniotic tissue repair markets with first sales already recorded and a US launch planned.